These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

847 related articles for article (PubMed ID: 25667169)

  • 61. Potentially multidrug-resistant non-fermentative Gram-negative pathogens causing nosocomial pneumonia.
    Ferrara AM
    Int J Antimicrob Agents; 2006 Mar; 27(3):183-95. PubMed ID: 16472990
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Old and new antibiotics for therapy of multidrug resistant bacteria].
    Pintado V
    Rev Esp Quimioter; 2016 Sep; 29 Suppl 1():39-42. PubMed ID: 27608312
    [TBL] [Abstract][Full Text] [Related]  

  • 63. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Fighting infections due to multidrug-resistant Gram-positive pathogens.
    Cornaglia G
    Clin Microbiol Infect; 2009 Mar; 15(3):209-11. PubMed ID: 19335367
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment.
    McDonald LC
    Clin Infect Dis; 2006 Jan; 42 Suppl 2():S65-71. PubMed ID: 16355319
    [TBL] [Abstract][Full Text] [Related]  

  • 66. In vitro activity of S-(3,4-dichlorobenzyl)isothiourea hydrochloride and novel structurally related compounds against multidrug-resistant bacteria, including Pseudomonas aeruginosa and Burkholderia cepacia complex.
    Nicholson A; Perry JD; James AL; Stanforth SP; Carnell S; Wilkinson K; Anjam Khan CM; De Soyza A; Gould FK
    Int J Antimicrob Agents; 2012 Jan; 39(1):27-32. PubMed ID: 21993484
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Antibiotics Clinical Development and Pipeline.
    Hesterkamp T
    Curr Top Microbiol Immunol; 2016; 398():447-474. PubMed ID: 26162565
    [TBL] [Abstract][Full Text] [Related]  

  • 68. New antibiotics for ventilator-associated pneumonia.
    Bassetti M; Vena A; Castaldo N; Righi E; Peghin M
    Curr Opin Infect Dis; 2018 Apr; 31(2):177-186. PubMed ID: 29337703
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Rapid antimicrobial susceptibility test for identification of new therapeutics and drug combinations against multidrug-resistant bacteria.
    Sun W; Weingarten RA; Xu M; Southall N; Dai S; Shinn P; Sanderson PE; Williamson PR; Frank KM; Zheng W
    Emerg Microbes Infect; 2016 Nov; 5(11):e116. PubMed ID: 27826141
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Future alternatives for the treatment of infections caused by carbapenemase-producing Enterobacteriaceae: what is in the pipeline?
    Horcajada JP; Torre-Cisneros J; Peña C; Fariñas MC
    Enferm Infecc Microbiol Clin; 2014 Dec; 32 Suppl 4():56-60. PubMed ID: 25542053
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Epidemiology of infections caused by multiresistant gram-negatives: ESBLs, MBLs, panresistant strains.
    Rossolini GM; Mantengoli E; Docquier JD; Musmanno RA; Coratza G
    New Microbiol; 2007 Jul; 30(3):332-9. PubMed ID: 17802921
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Synergistic activity profile of an antimicrobial peptide against multidrug-resistant and extensively drug-resistant strains of Gram-negative bacterial pathogens.
    Pollini S; Brunetti J; Sennati S; Rossolini GM; Bracci L; Pini A; Falciani C
    J Pept Sci; 2017 Apr; 23(4):329-333. PubMed ID: 28176481
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Antimicrobial susceptibilities of organisms isolated from patients with urinary tract infections in 2002].
    Eta S; Kawahara M
    Jpn J Antibiot; 2006 Feb; 59(1):21-8. PubMed ID: 16673579
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Collateral benefit of screening patients for methicillin-resistant Staphylococcus aureus at hospital admission: isolation of patients with multidrug-resistant gram-negative bacteria.
    Jones M; Nielson C; Gupta K; Khader K; Evans M
    Am J Infect Control; 2015 Jan; 43(1):31-4. PubMed ID: 25442394
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Is screening patients for antibiotic-resistant bacteria justified in the Indian context?
    Bhattacharya S
    Indian J Med Microbiol; 2011; 29(3):213-7. PubMed ID: 21860099
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Photoinactivation of ESKAPE pathogens: overview of novel therapeutic strategy.
    Nakonieczna J; Wozniak A; Pieranski M; Rapacka-Zdonczyk A; Ogonowska P; Grinholc M
    Future Med Chem; 2019 Mar; 11(5):443-461. PubMed ID: 30901231
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Infections by multidrug-resistant Gram-negative Bacteria: What's new in our arsenal and what's in the pipeline?
    Koulenti D; Song A; Ellingboe A; Abdul-Aziz MH; Harris P; Gavey E; Lipman J
    Int J Antimicrob Agents; 2019 Mar; 53(3):211-224. PubMed ID: 30394301
    [TBL] [Abstract][Full Text] [Related]  

  • 78. In Vitro Screening of an FDA-Approved Library Against ESKAPE Pathogens.
    Younis W; AbdelKhalek A; Mayhoub AS; Seleem MN
    Curr Pharm Des; 2017; 23(14):2147-2157. PubMed ID: 28190396
    [TBL] [Abstract][Full Text] [Related]  

  • 79. New treatment options for multiresistant gram negatives.
    Paterson DL; Isler B; Stewart A
    Curr Opin Infect Dis; 2020 Apr; 33(2):214-223. PubMed ID: 32068644
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Ceftazidime/Avibactam and Ceftolozane/Tazobactam for Multidrug-Resistant Gram Negatives in Patients with Hematological Malignancies: Current Experiences.
    Criscuolo M; Trecarichi EM
    Antibiotics (Basel); 2020 Feb; 9(2):. PubMed ID: 32028615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.